The bi-steric mTORC1-selective inhibitor RMC-5552 is now in human clinical trials and, based on the results presented herein, has the potential to benefit patients with TSC syndrome tumors, and patients with the common cancers in which TSC1/TSC2 mutations drive hyperactivated mTORC1 activity. This evidence concerns the gene TSC1 and cancer.